Study of REGN2810 in Adults With Cervical Cancer

Condition:   Recurrent or Metastatic, Platinum-refractory Cervical Cancer
Interventions:   Drug: REGN2810;   Drug: Investigator Choice (IC) Chemotherapy
Sponsors:   Regeneron Pharmaceuticals;   Sanofi
Recruiting

http://ift.tt/2nUcA6P